3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Prostatic Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Neoplasms
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
7
padeliporfin
5
Nivolumab
4
Everolimus
4
Sunitinib
3
Sorafenib
3
Mitomycin
3
fludarabine
2
epothilone B
2
durvalumab
2
cabozantinib
2
Ipilimumab
2
Cyclophosphamide
2
Cisplatin
2
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
2
volociximab
1
vinflunine
1
sipuleucel-T
1
sargramostim
1
pemigatinib
1
palladium-bacteriopheophorbide
1
palbociclib
1
obinutuzumab
1
luprolide acetate gel depot
1
lenvatinib
1
ixabepilone
1
fludarabine phosphate
1
enzalutamide
1
belzutifan
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
Solutions
×
Genitourinary
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled